Federal inspectors found that Ashland Post Acute violated informed consent requirements for Resident 7, who was admitted in May 2025 with depression among other diagnoses. The facility's director of nursing services confirmed to inspectors that staff never reviewed the medication information with the resident and obtained no signed consent.
The violation came to light during a November complaint investigation at the 135 Maple Street facility. Inspectors reviewed medical records for three residents receiving psychotropic medications and found the consent failure affected at least one person.
Physician orders from May 3, 2025 show Resident 7 began receiving Lexapro shortly after admission. The antidepressant continued daily through the November inspection. Medical records contained no documentation that anyone explained the drug's potential benefits or warned about possible side effects.
Staff 2, identified as the director of nursing services, admitted the oversight during an interview with inspectors on November 13 at 11:23 AM. The nursing director verified that risks and benefits information was never reviewed with Resident 7.
Federal regulations require nursing homes to fully inform residents about their health status, care and treatments. For psychiatric medications like antidepressants, facilities must explain both potential benefits and risks before starting treatment. Residents have the right to understand what medications they're receiving and why.
The inspection report classified the violation as causing minimal harm or potential for actual harm to residents. However, the failure placed Resident 7 at risk for being uninformed about a medication affecting brain chemistry and mood.
Lexapro belongs to a class of antidepressants called selective serotonin reuptake inhibitors. These medications can cause side effects including nausea, drowsiness, sexual dysfunction, and withdrawal symptoms if stopped abruptly. In rare cases, antidepressants may increase suicidal thoughts, particularly in younger patients.
The informed consent process serves as a critical safeguard for nursing home residents, many of whom have cognitive impairments or depend entirely on staff for medical information. Without proper disclosure, residents cannot make informed decisions about their psychiatric treatment.
Ashland Post Acute's violation suggests systemic problems with medication management protocols. The facility's nursing leadership acknowledged they failed to follow basic consent procedures for psychiatric medications.
The November 14 inspection focused on specific complaints rather than a comprehensive facility review. Inspectors examined medication practices for just three residents, finding the consent violation affected at least one person. The report noted "few" residents were affected overall.
This type of informed consent failure has drawn increased federal scrutiny at nursing homes nationwide. Psychiatric medications are frequently prescribed in long-term care settings, making proper consent procedures essential for resident rights and safety.
The facility must submit a plan of correction addressing how it will ensure proper informed consent for all psychotropic medications. Federal regulations require approved corrective action plans for continued Medicare and Medicaid participation.
For Resident 7, six months passed without understanding the antidepressant being administered daily. The person received Lexapro throughout the spring and summer of 2025, unaware of potential benefits that might improve depression symptoms or risks that could cause unwanted effects.
The violation occurred despite clear federal requirements that nursing homes inform residents about their medications. Staff had multiple opportunities during the six-month period to provide the required information and obtain proper consent.
Ashland Post Acute's director of nursing services confirmed to federal inspectors that the facility simply failed to follow established protocols for psychiatric medication consent. The admission came only after investigators discovered the missing documentation during their complaint review.
The inspection report provides no indication that Resident 7 experienced adverse effects from the undisclosed Lexapro treatment. However, the lack of informed consent violated the person's fundamental right to understand their medical care.
Federal inspectors completed their investigation on November 14, 2025, documenting the consent violation as part of their complaint review. The facility now faces federal oversight until it demonstrates compliance with informed consent requirements for all psychiatric medications.
Full Inspection Report
The details above represent a summary of key findings. View the complete inspection report for Ashland Post Acute from 2025-11-14 including all violations, facility responses, and corrective action plans.